580 related articles for article (PubMed ID: 15270726)
1. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
2. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
4. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
5. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
Vinay DS; Kwon BS
Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
[TBL] [Abstract][Full Text] [Related]
8. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
9. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
[TBL] [Abstract][Full Text] [Related]
10. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
11. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans.
Garni-Wagner BA; Lee ZH; Kim YJ; Wilde C; Kang CY; Kwon BS
Cell Immunol; 1996 Apr; 169(1):91-8. PubMed ID: 8612300
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.
Choi BK; Bae JS; Choi EM; Kang WJ; Sakaguchi S; Vinay DS; Kwon BS
J Leukoc Biol; 2004 May; 75(5):785-91. PubMed ID: 14694186
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of CD8(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses.
Villacres MC; Zuo J; Bergmann CC
Virology; 2000 Apr; 270(1):54-64. PubMed ID: 10772979
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB-mediated immunotherapy of rheumatoid arthritis.
Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS
Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
Dawicki W; Bertram EM; Sharpe AH; Watts TH
J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
[TBL] [Abstract][Full Text] [Related]
19. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.
Tan JT; Ha J; Cho HR; Tucker-Burden C; Hendrix RC; Mittler RS; Pearson TC; Larsen CP
Transplantation; 2000 Jul; 70(1):175-83. PubMed ID: 10919597
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB costimulation enhances HSV-1-specific CD8+ T cell responses by the induction of CD11c+CD8+ T cells.
Kim YH; Seo SK; Choi BK; Kang WJ; Kim CH; Lee SK; Kwon BS
Cell Immunol; 2005 Dec; 238(2):76-86. PubMed ID: 16524567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
